atai Life Sciences to Participate in Upcoming June Healthcare Conferences

NEW YORK and BERLIN, June 16, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following upcoming healthcare conferences in June:

• BIO International Conference

                        Format: Company Presentation – In Person
                        Date and Time: Thursday, June 16^th, 2:45 p.m. ET – 3:15 p.m. ET
                        Conference Link: URL

• H.C. Wainwright 1^st Annual Mental Health Conference

                        Format: Company Presentation – Hybrid
                        Date and Time: Monday, June 27^th, 12:00 p.m. ET – 12:30 p.m. ET
                        Conference Link: URL

The presentation and archived webcast will also be accessible in the Events section of atai’s website.

About atai Life Sciences
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

atai’s business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and non-psychedelic compounds with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders.

atai’s vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life. For more information, please visit www.atai.life.

Forward-Looking Statements
These presentations may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in these presentations that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as updated by our subsequent filings with the SEC, as such factors may be updated from time to time in atai’s other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Contact Information

Investor Contact:
Greg Weaver,
Chief Financial Officer, atai Life Sciences
Email: IR@atai.life

Media Contact:
Allan Malievsky,
Senior Director, External Affairs
Email: allan@atai.life